International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

Michael Charlton; Josh Levitsky; Bashar Aqel; John O'Grady; Julie Hemibach; Mary Rinella; John Fung; Marwan Ghabril; Ray Thomason; Patrizia Burra; Ester Coelho Little; Marina Berenguer; Abraham Shaked; James Trotter; John Roberts; Manuel Rodriguez-Davalos; Mohamed Rela; Elizabeth Pomfret; Caroline Heyrend; Juan Gallegos-Orozco; Faouzi Saliba

doi:10.1097/TP.0000000000002147

International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

Michael Charlton, Josh Levitsky, Bashar Aqel, John O'Grady, Julie Hemibach, Mary Rinella, John Fung, Marwan Ghabril, Ray Thomason, Patrizia Burra, Ester Coelho Little, Marina Berenguer, Abraham Shaked, James Trotter, John Roberts, Manuel Rodriguez-Davalos, Mohamed Rela, Elizabeth Pomfret, Caroline Heyrend, Juan Gallegos-OrozcoFaouzi Saliba

Research output: Contribution to journal › Review article › peer-review

43 Scopus citations

Abstract

Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.

Original language	English (US)
Pages (from-to)	727-743
Number of pages	17
Journal	Transplantation
Volume	102
Issue number	5
DOIs	https://doi.org/10.1097/TP.0000000000002147
State	Published - May 1 2018

ASJC Scopus subject areas

Transplantation

Access to Document

10.1097/TP.0000000000002147

Cite this

Charlton, M., Levitsky, J., Aqel, B., O'Grady, J., Hemibach, J., Rinella, M., Fung, J., Ghabril, M., Thomason, R., Burra, P., Little, E. C., Berenguer, M., Shaked, A., Trotter, J., Roberts, J., Rodriguez-Davalos, M., Rela, M., Pomfret, E., Heyrend, C., ... Saliba, F. (2018). International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation, 102(5), 727-743. https://doi.org/10.1097/TP.0000000000002147

Charlton, M, Levitsky, J, Aqel, B, O'Grady, J, Hemibach, J, Rinella, M, Fung, J, Ghabril, M, Thomason, R, Burra, P, Little, EC, Berenguer, M, Shaked, A, Trotter, J, Roberts, J, Rodriguez-Davalos, M, Rela, M, Pomfret, E, Heyrend, C, Gallegos-Orozco, J & Saliba, F 2018, 'International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients', Transplantation, vol. 102, no. 5, pp. 727-743. https://doi.org/10.1097/TP.0000000000002147

@article{de1366bf8a444283bbdc4f9e6f140de4,

title = "International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients",

abstract = "Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.",

author = "Michael Charlton and Josh Levitsky and Bashar Aqel and John O'Grady and Julie Hemibach and Mary Rinella and John Fung and Marwan Ghabril and Ray Thomason and Patrizia Burra and Little, {Ester Coelho} and Marina Berenguer and Abraham Shaked and James Trotter and John Roberts and Manuel Rodriguez-Davalos and Mohamed Rela and Elizabeth Pomfret and Caroline Heyrend and Juan Gallegos-Orozco and Faouzi Saliba",

year = "2018",

month = may,

day = "1",

doi = "10.1097/TP.0000000000002147",

language = "English (US)",

volume = "102",

pages = "727--743",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

AU - Charlton, Michael

AU - Levitsky, Josh

AU - Aqel, Bashar

AU - O'Grady, John

AU - Hemibach, Julie

AU - Rinella, Mary

AU - Fung, John

AU - Ghabril, Marwan

AU - Thomason, Ray

AU - Burra, Patrizia

AU - Little, Ester Coelho

AU - Berenguer, Marina

AU - Shaked, Abraham

AU - Trotter, James

AU - Roberts, John

AU - Rodriguez-Davalos, Manuel

AU - Rela, Mohamed

AU - Pomfret, Elizabeth

AU - Heyrend, Caroline

AU - Gallegos-Orozco, Juan

AU - Saliba, Faouzi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.

AB - Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.

UR - http://www.scopus.com/inward/record.url?scp=85046537542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046537542&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000002147

DO - 10.1097/TP.0000000000002147

M3 - Review article

AN - SCOPUS:85046537542

SN - 0041-1337

VL - 102

SP - 727

EP - 743

JO - Transplantation

JF - Transplantation

IS - 5

ER -

International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this